2019
Immunotherapy of Melanoma: Facts and Hopes
Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research 2019, 25: 5191-5201. PMID: 30923036, PMCID: PMC6726509, DOI: 10.1158/1078-0432.ccr-18-1550.Peer-Reviewed Original ResearchConceptsOverall survivalMetastatic diseaseImmune therapyPredictive biomarkersNivolumab/ipilimumab combinationRandomized phase III trialLong-term clinical benefitImmunobiology of tumorsDuration of therapyPhase III trialsLong-term survivorsEffective immune therapyAdjuvant settingIpilimumab combinationMetastatic settingIII trialsPatient subsetsClinical benefitImmune modulationMetastatic melanomaClinical trialsSingle agentTherapyTrue increaseCell therapy
2014
Update on Vaccines for High-Risk Melanoma
Weiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.Peer-Reviewed Original ResearchConceptsHigh-risk melanomaRole of vaccinesClinical trialsCytotoxic T-lymphocyte antigen-4Death-1 monoclonal antibodyT-lymphocyte antigen-4Cell death-1 monoclonal antibodyImmunogenic solid tumorsOpinion statementThe managementPrimary surgical resectionHigh-risk diseaseMeaningful clinical responsesGranulocyte-macrophage colony-stimulating factorImmune stimulatory agentsDevelopment of vaccinesMacrophage colony-stimulating factorColony-stimulating factorAdjuvant settingImmunomodulatory therapyAdjuvant optionClinical responseMelanoma vaccineSurgical resectionVaccine therapyClinical outcomes